A Five-Year Trend Analysis of USFDA Expedited Approvals and Designations for New Drug Applications (2020–2024)

Key Points

• Expedited approvals for new drug applications have increased over the past five years, indicating regulatory responsiveness.
• In 2021, there were 95 new drug applications approved, with a significant percentage receiving expedited designations.
• This observational analysis examines pattern shifts in drug approvals via expedited pathways since 2020.
• Regulatory bodies may need to adapt as the demand for rapid drug approval increases, indicating evolving healthcare needs.